A first-in-man clinical trial of Micropump sodium oxybate in healthy volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Sodium oxybate (Primary)
- Indications Narcolepsy
- Focus Adverse reactions; Pharmacokinetics
- 03 Jan 2017 This trial was planned by Flamel Technologies. The company has completed cross-border merger and became Avadel Pharmaceuticals plc, according to a Flamel Technologies media release.
- 12 Jan 2016 Planned End Date changed to 1 Jun 2017.
- 08 Jan 2016 According to Flamel Technologies media release, target for completing this trial remains mid-2017.